PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed

Advanced or metastatic cervical cancer has a poor prognosis, and the 5-year overall survival is <5% with conventional radiotherapy and chemotherapy. Immunotherapy, particularly immune checkpoint inhibitors (ICIs), achieved initial success in advanced solid tumors, while their efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Weijia, Liu, Jiewei, Xu, Kai, Chen, Huilin, Bian, Ce
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614140/
https://www.ncbi.nlm.nih.gov/pubmed/36313730
http://dx.doi.org/10.3389/fonc.2022.849352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9614140/
https://www.ncbi.nlm.nih.gov/pubmed/36313730
http://dx.doi.org/10.3389/fonc.2022.849352

Ejemplares similares